Pharmacogenetics and response to β-adrenergic receptor antagonists in heart failure

Clinical Pharmacology and Therapeutics

Volumn 77, Issue 3, 2005, Pages 123-126

  Muszkat, Mordechai ^a   Stein, C Michael ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CYTOCHROME P450 2D6; ISOPRENALINE; METOPROLOL;

AGE; ALLELE; BRADYCARDIA; DISEASE EXACERBATION; DISEASE SEVERITY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; GENE FREQUENCY; GENETIC VARIABILITY; HEART FAILURE; HUMAN; HYPOTENSION; NONHUMAN; NOTE; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; HEART FAILURE, CONGESTIVE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 13944250330     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.10.007     Document Type: Note

References (29)

1. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 1999;83:1A-38A.
2. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
3. H. Krum, E.B. Roecker, P. Mohacsi, J.L. Rouleau, M. Tendera, A.J. Coats Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study JAMA 289 2003 712 718
4. A. Leizorovicz, P. Lechat, M. Cucherat, F. Bugnard Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II Cardiac Insufficiency Bisoprolol Study. Am Heart J 143 2002 301 307
5. C. Zugck, A. Haunstetter, C. Kruger, R. Kell, D. Schellberg, W. Kubler Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure J Am Coll Cardiol 39 2002 1615 1622
6. D.D. Sin, F.A. McAlister The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure Am J Med 113 2002 650 656
7. S.S. Gottlieb, M.L. Fisher, J. Kjekshus, P. Deedwania, L. Gullestad, J. Vitovec Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) Circulation 105 2002 1182 1188
8. P.S. Macdonald, A.M. Keogh, C.L. Aboyoun, M. Lund, R. Amor, D.J. McCaffrey Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure J Am Coll Cardiol 33 1999 924 931
9. F. Waagstein, M.R. Bristow, K. Swedberg, F. Camerini, M.B. Fowler, M.A. Silver Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group Lancet 342 1993 1441 1446
10. A.J. Baxter, A. Spensley, A. Hildreth, G. Karimova, J.E. O'Connell, C.S. Gray Beta blockers in older persons with heart failure: tolerability and impact on quality of life Heart 88 2002 611 614
11. H. Wuttke, T. Rau, R. Heide, K. Bergmann, M. Bohm, J. Weil Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects Clin Pharmacol Ther 72 2002 429 437
12. G.G. Sofowora, V. Dishy, M. Muszkat, H.G. Xie, R.B. Kim, P.A. Harris A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade Clin Pharmacol Ther 73 2003 366 371
13. 1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol Clin Pharmacol Ther 74 2003 44 52
14. J. Liu, Z.Q. Liu, Z.R. Tan, X.P. Chen, L.S. Wang, G. Zhou Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol Clin Pharmacol Ther 74 2003 372 379
15. I. Zineh, A.L. Beitelshees, A. Gaedigk, J.R. Walker, D.F. Pauly, K. Eberst Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension Clin Pharmacol Ther 76 2004 536 544
16. M.S. Lennard, J.H. Silas, S. Freestone, L.E. Ramsay, G.T. Tucker, H.F. Woods Oxidation phenotype--a major determinant of metoprolol metabolism and response N Engl J Med 307 1982 1558 1560
17. J.C. McGourty, J.H. Silas, M.S. Lennard, G.T. Tucker, H.F. Woods Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies Br J Clin Pharmacol 20 1985 555 566
18. B.A. Hamelin, A. Bouayad, J. Methot, J. Jobin, P. Desgagnes, P. Poirier Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity Clin Pharmacol Ther 67 2000 466 477
19. T. Giessmann, C. Modess, U. Hecker, M. Zschiesche, P. Dazert, C. Kunert-Keil CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects Clin Pharmacol Ther 75 2004 213 222
20. D.W.J. Clack, A.K.W. Morgan, H. Waal-Manning Adverse effects from metoprolol are not generally associated with oxidation status [letter] Br J Clin Pharmacol 18 1984 965 967
21. A. Maqbool, A.S. Hall, S.G. Ball, A.J. Balmforth Common polymorphisms of beta1-adrenoceptor: identification and rapid screening assay [letter] Lancet 353 1999 897
22. J.D. Moore, D.A. Mason, S.A. Green, J. Hsu, S.B. Liggett Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C Hum Mutat 14 1999 271
23. D.A. Rathz, K.M. Brown, L.A. Kramer, S.B. Liggett Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking J Cardiovasc Pharmacol 39 2002 155 160
24. D.A. Mason, J.D. Moore, S.A. Green, S.B. Liggett A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor J Biol Chem 274 1999 12670 12674
25. R. Ginsburg, M.R. Bristow, M.E. Billingham, E.B. Stinson, J.S. Schroeder, D.C. Harrison Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol Am Heart J 106 1983 535 540
26. M.R. Bristow, R. Ginsburg, W. Minobe, R.S. Cubiccioti, W.S. Segman, K. Lurie Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts N Engl J Med 307 1982 205 211
27. S.M. Heilbrunn, P. Shah, M.R. Bristow, H.A. Valantine, R. Ginsburg, M.B. Fowler Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy Circulation 79 1989 483 490
28. J.M. Perez, D.A. Rathz, N.N. Petrashevskaya, H.S. Hahn, L.E. Wagoner, A. Schwartz Beta1-Adrenergic receptor polymorphisms confer differential function and predisposition to heart failure Nat Med 9 2003 1300 1305
29. S.G. Terra, D.F. Pauly, C.R. Lee, J.H. Patterson, K.F. Adams Jr, R.S. Schofield β-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure Clin Pharmacol Ther 77 2005 127 137